Immune-related adverse events and the balancing act of immunotherapy COMMENT

被引:215
作者
Conroy, Michael [1 ,2 ,3 ]
Naidoo, Jarushka [1 ,2 ,3 ,4 ]
机构
[1] Beaumont RCSI Canc Ctr, Dublin, Ireland
[2] Beaumont Hosp, Dublin, Ireland
[3] RCSI Univ Hlth Sci, Dublin, Ireland
[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA
关键词
PNEUMONITIS;
D O I
10.1038/s41467-022-27960-2
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.
引用
收藏
页数:4
相关论文
共 20 条
[1]   Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors [J].
Ali, Omar Hasan ;
Berner, Fiamma ;
Bomze, David ;
Fassler, Mirjam ;
Diem, Stefan ;
Cozzio, Antonio ;
Jorger, Markus ;
Fruh, Martin ;
Driessen, Christoph ;
Lenz, Tobias L. ;
Flatz, Lukas .
EUROPEAN JOURNAL OF CANCER, 2019, 107 :8-14
[2]   Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].
Arbour, Kathryn C. ;
Mezquita, Laura ;
Long, Niamh ;
Rizvi, Hira ;
Auclin, Edouard ;
Ni, Andy ;
Martinez-Bernal, Gala ;
Ferrara, Roberto ;
Lai, W. Victoria ;
Hendriks, Lizza E. L. ;
Sabari, Joshua K. ;
Caramella, Caroline ;
Plodkowski, Andrew J. ;
Halpenny, Darragh ;
Chaft, Jamie E. ;
Planchard, David ;
Riely, Gregory J. ;
Besse, Benjamin ;
Hellmann, Matthew D. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+
[3]  
Balaji A, J IMMUNOTHER CANCER, V9
[4]   Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors [J].
Dall'Olio, Filippo G. ;
Di Nunno, Vincenzo ;
Massari, Francesco .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) :105-+
[5]   Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial [J].
Eggermont, Alexander M. M. ;
Kicinski, Michal ;
Blank, Christian U. ;
Mandala, Mario ;
Long, Georgina V. ;
Atkinson, Victoria ;
Dalle, Stephane ;
Haydon, Andrew ;
Khattak, Adnan ;
Carlino, Matteo S. ;
Sandhu, Shahneen ;
Larkin, James ;
Puig, Susana ;
Ascierto, Paolo A. ;
Rutkowski, Piotr ;
Schadendorf, Dirk ;
Koornstra, Rutger ;
Hernandez-Aya, Leonel ;
Di Giacomo, Anna Maria ;
van den Eertwegh, Alfonsus J. M. ;
Grob, Jean-Jacques ;
Gutzmer, Ralf ;
Jamal, Rahima ;
Lorigan, Paul C. ;
Krepler, Clemens ;
Ibrahim, Nageatte ;
Marreaud, Sandrine ;
van Akkooi, Alexander ;
Robert, Caroline ;
Suciu, Stefan .
JAMA ONCOLOGY, 2020, 6 (04) :519-527
[6]   Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors [J].
Guidon, Amanda C. ;
Burton, Leeann B. ;
Chwalisz, Bart K. ;
Hillis, James ;
Schaller, Teilo H. ;
Amato, Anthony A. ;
Warner, Allison Betof ;
Brastianos, Priscilla K. ;
Cho, Tracey A. ;
Clardy, Stacey L. ;
Cohen, Justine, V ;
Dietrich, Jorg ;
Dougan, Michael ;
Doughty, Christopher T. ;
Dubey, Divyanshu ;
Gelfand, Jeffrey M. ;
Guptill, Jeffrey T. ;
Johnson, Douglas B. ;
Juel, Vern C. ;
Kadish, Robert ;
Kolb, Noah ;
LeBoeuf, Nicole R. ;
Linnoila, Jenny ;
Mammen, Andrew L. ;
Martinez-Lage, Maria ;
Mooradian, Meghan J. ;
Naidoo, Jarushka ;
Neilan, Tomas G. ;
Reardon, David A. ;
Rubin, Krista M. ;
Santomasso, Bianca D. ;
Sullivan, Ryan J. ;
Wang, Nancy ;
Woodman, Karin ;
Zubiri, Leyre ;
Louv, William C. ;
Reynolds, Kerry L. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
[7]   Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial [J].
Hodi, Frank Stephen ;
Chiarion-Sileni, Vanna ;
Gonzalez, Rene ;
Grob, Jean-Jacques ;
Rutkowski, Piotr ;
Cowey, Charles Lance ;
Lao, Christopher D. ;
Schadendorf, Dirk ;
Wagstaff, John ;
Dummer, Reinhard ;
Ferrucci, Pier Francesco ;
Smylie, Michael ;
Hill, Andrew ;
Hogg, David ;
Marquez-Rodas, Ivan ;
Jiang, Joel ;
Rizzo, Jasmine ;
Larkin, James ;
Wolchok, Jedd D. .
LANCET ONCOLOGY, 2018, 19 (11) :1480-1492
[8]   Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody [J].
Maher, V. Ellen ;
Fernandes, Laura L. ;
Weinstock, Chana ;
Tang, Shenghui ;
Agarwal, Sundeep ;
Brave, Michael ;
Ning, Yang-min ;
Singh, Harpreet ;
Suzman, Daniel ;
Xu, James ;
Goldberg, Kirsten B. ;
Sridhara, Rajeshwari ;
Ibrahim, Amna ;
Theoret, Marc ;
Beaver, Julia A. ;
Pazdur, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2730-+
[9]   A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events [J].
Naidoo, Jarushka ;
Zhang, Jiajia ;
Lipson, Evan J. ;
Forde, Patrick M. ;
Suresh, Karthik ;
Moseley, Kendall F. ;
Mehta, Seema ;
Kwatra, Shawn G. ;
Parian, Alyssa M. ;
Kim, Amy K. ;
Probasco, John C. ;
Rouf, Rosanne ;
Thorne, Jennifer E. ;
Shanbhag, Satish ;
Riemer, Joanne ;
Shah, Ami A. ;
Pardoll, Drew M. ;
Bingham, Clifton O., III ;
Brahmer, Julie R. ;
Cappelli, Laura C. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06) :712-720
[10]   Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy [J].
Naidoo, Jarushka ;
Wang, Xuan ;
Woo, Kaitlin M. ;
Iyriboz, Tunc ;
Halpenny, Darragh ;
Cunningham, Jane ;
Chaft, Jamie E. ;
Segal, Neil H. ;
Callahan, Margaret K. ;
Lesokhin, Alexander M. ;
Rosenberg, Jonathan ;
Voss, Martin H. ;
Rudin, Charles M. ;
Rizvi, Hira ;
Hou, Xue ;
Rodriguez, Katherine ;
Albano, Melanie ;
Gordon, Ruth-Ann ;
Leduc, Charles ;
Rekhtman, Natasha ;
Harris, Bianca ;
Menzies, Alexander M. ;
Guminski, Alexander D. ;
Carlino, Matteo S. ;
Kong, Benjamin Y. ;
Wolchok, Jedd D. ;
Postow, Michael A. ;
Long, Georgina V. ;
Hellmann, Matthew D. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) :709-+